Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-06-12
2007-06-12
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S210020, C514S460000
Reexamination Certificate
active
10625004
ABSTRACT:
The instant invention provides a pharmaceutical composition comprised of a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor, one or more anti-oxidants, microcrystalline cellulose, hydroxypropyl methylcellulose, magnesium stearate and lactose. The composition need not contain ascorbic acid in order to obtain desirable stability.
REFERENCES:
patent: 4444784 (1984-04-01), Hoffman et al.
patent: 4990535 (1991-02-01), Cho et al.
patent: 5100675 (1992-03-01), Cho et al.
patent: 5145684 (1992-09-01), Liversidge et al.
patent: 5162117 (1992-11-01), Stupak et al.
patent: 5366738 (1994-11-01), Rork et al.
patent: 5612367 (1997-03-01), Timko et al.
patent: 5622985 (1997-04-01), Olukotun et al.
patent: 5627176 (1997-05-01), Kirkup et al.
patent: 5631365 (1997-05-01), Rosenblum et al.
patent: 5656624 (1997-08-01), Vaccaro et al.
patent: 5661145 (1997-08-01), Davis
patent: 5674893 (1997-10-01), Behounek et al.
patent: 5688785 (1997-11-01), Vaccaro
patent: 5688787 (1997-11-01), Burnett et al.
patent: 5691375 (1997-11-01), Behounek et al.
patent: 5756470 (1998-05-01), Yumibe et al.
patent: 5767115 (1998-06-01), Rosenblum et al.
patent: 5807834 (1998-09-01), Morehouse
patent: 5846966 (1998-12-01), Rosenblum et al.
patent: 5976570 (1999-11-01), Greaves et al.
patent: 6099865 (2000-08-01), Augello et al.
patent: 6110493 (2000-08-01), Guentensberger et al.
patent: 6207822 (2001-03-01), Thiruvengadam et al.
patent: 6218403 (2001-04-01), Daste et al.
patent: 6235706 (2001-05-01), Gould et al.
patent: 6251852 (2001-06-01), Gould et al.
patent: 6372255 (2002-04-01), Saslawski et al.
patent: RE37721 (2002-05-01), Rosenblum et al.
patent: 6420417 (2002-07-01), Keller et al.
patent: 6569461 (2003-05-01), Tillyer et al.
patent: 2002/0006919 (2002-01-01), Thosar et al.
patent: 0276807 (1988-08-01), None
patent: 0457514 (1996-08-01), None
patent: WO 88/05296 (1988-08-01), None
patent: WO 94/14433 (1994-07-01), None
patent: WO 95/08532 (1995-03-01), None
patent: WO 96/09827 (1996-04-01), None
patent: WO 98/46215 (1998-10-01), None
patent: WO 99/66929 (1999-12-01), None
patent: WO 99/66930 (1999-12-01), None
patent: WO 00/32189 (2000-06-01), None
patent: WO 00/53149 (2000-09-01), None
patent: WO 00/53173 (2000-09-01), None
patent: WO 00/53566 (2000-09-01), None
patent: WO 01/08686 (2001-02-01), None
patent: WO 01/45676 (2001-06-01), None
patent: WO 01/49267 (2001-07-01), None
patent: WO 01/64221 (2001-09-01), None
patent: WO 02/058696 (2002-08-01), None
patent: WO 02/058731 (2002-08-01), None
patent: WO 02/058732 (2002-08-01), None
patent: WO 02/058733 (2002-08-01), None
patent: WO 02/058734 (2002-08-01), None
Handbook of Pharmaceutical Excipients, published by American Pharmaceutical Association in 1986, see pp. 78,79,108-110, and 234-239.
STN Registry file monograph of Registry No. 163222-33-1, “Ezetimibe”, entered in data base on May 24, 1995.
Harrison's Principles of Internal Medicine, 13thEdition, vol. 1, published 1994 by McGraw-Hill, Inc. (NY), pp. 1108-1116.
Merck Frosst Canada Ltd., “Product Monograph ZOCOR®”, no date available.
Electronic online Physician's Desk Reference entry for ZOCOR® (“Description” section), no date avaiable.
Canadian ZOCOR® Product Monograph, no date available.
SINVACOR® 20 mg package (Italian), no date available.
Attachment to Approval Decree for SINVACOR® 10 mg (Italian), no date available.
Gagne, C., et al.., Circulation, American Heart Association, vol. 105, No. 21, pp. 2469-2475, 2002.
Davidson, Michael, et al., Journal of the American College of Cardiology, vol. 39, No. 5, pp. 226A-227A, 2002.
Arthur H. Kibbe, Handbook of Pharmaceutical Excipients—Third Edition, pp. 47 and 49, date unavailable.
Davidson, Michael, et al., Journal of the American College of Cardiology, vol. 40, No. 12, pp. 2125-2134 2002.
Fitzpatrick Shaun
Moore William D.
Petts Catherine R.
Saklatvala Robert
Seiler Christian
Foley & Lardner LLP
Henley III Raymond J.
LandOfFree
Pharmaceutical formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical formulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3832618